Anticoagulant-related bleeding in older persons with atrial fibrillation: Physicians' fears often unfounded

Archives of Internal Medicine

Volumn 163, Issue 13, 2003, Pages 1580-1586

  Man Son Hing, Malcolm ^a,c   Laupacis, Andreas ^b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; WARFARIN;

AGED; AGING; ALCOHOLISM; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLEEDING TENDENCY; BRAIN HEMORRHAGE; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG INDICATION; FALLING; HEART ATRIUM FIBRILLATION; HUMAN; MEDICAL DECISION MAKING; MEDLINE; META ANALYSIS; PATIENT COMPLIANCE; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; RISK ASSESSMENT; RISK FACTOR; STROKE; THROMBOCYTOPENIA; UPPER GASTROINTESTINAL BLEEDING;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; HEMORRHAGE; HUMANS; RISK FACTORS;

EID: 0037817710     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.163.13.1580     Document Type: Article

References (86)

1. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Arch Intern Med. 1995; 155:469-473.
2. Albers GW, Dalen JE, Laupacis A, Manning WJ, Petersen P, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest. 2001;119(suppl):194S-206S.
3. Gage BF, Waterman AD, Shannon W, Boechler M, Rich M, Radford MJ. Validation of clinical classification schemes for predicting stroke. JAMA. 2001;285: 2864-2870.
4. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999; 131:492-501.
5. Atrial Fibrillation Investigators. Atrial fibrillation; risk factors for embolization and efficacy of antithrombotic therapy. Arch Intern Med. 1994;154:1449-1457.
6. Atrial Fibrillation Investigators, The efficacy of aspirin in patients with atrial fibrillation: analysis of pooled data from 3 randomized trials. Arch Intern Med. 1997; 157:1237-1240.
7. Gage BF, Cardinalli AB, Albers GW, Owens DK. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA. 1995;274:1839-1845.
8. Lightowlers S, McGuire A. Cost-effectiveness of anticoagulation in nonrheumatic atrial fibrillation in the primary prevention of ischemic stroke. Stroke. 1998; 29:1827-1832.
9. Gustafsson C, Asplund K, Britton M, Norrving B, Olsson B, Marke LA. Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective. BMJ. 1992;305:1457-1460.
10. Arnsten JH, Gelfand JM, Singer DE. Determinants of compliance with anticoagulation: a case-control study. Am J Med. 1997;103:11-17.
11. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med. 1993;153:1665-1670.
12. Lundstrom T, Ryden L. Hemorrhagic and thromboembolic complications in patients with atrial fibrillation on anticoagulant prophylaxis. J Intern Med. 1989; 225:137-142.
13. Beyth RJ, Antani MR, Covinsky KE, et al. Why isn't warfarin prescribed to patients with nonrheumatic atrial fibrillation? J Gen Intern Med. 1996;11:721-728.
14. Man-Son-Hing M, Laupacis A. Balancing the risks of stroke and gastrointestinal bleeding in older persons with atrial fibrillation. Arch Intern Med. 2002;162:541-550.
15. Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med. 1999;159:677-685.
16. Labenz J, Borsch G. Role of Helicobacter pylori eradication in the prevention of peptic ulcer bleeding relapse. Digestion. 1994;55:19-23.
17. Rokkas T, Karameris A, Mavrogeorgis A, Rallis E, Giannikos N. Eradication of Helicobacter pylori reduces the possibility of rebleeding in peptic ulcer disease, Gastrointest Endosc. 1995;41:1-4.
18. Garrigan K, McIntosh C, Fraser AG. Bleeding peptic ulcers: audit of eradication treatment for H. pylori. N Z Med J. 1999;112:178-180.
19. Hernandez-Diaz S, Garcia Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med. 2000; 160:2093-2099.
20. Yeomans ND, Tulassay Z, Juhasz L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 1998;338:719-726
21. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. Ann Intern Med. 1995;123:241-249.
22. Langman MJ, Jensen DM, Watson DJ, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA. 1999;282:1929-1933.
23. Saloheimo P, Juvela S, Hillbom M. Use of aspirin, epistaxis, and untreated hypertension as risk factors for primary intracerebral hemorrhage in middle-aged and elderly people. Stroke. 2001;32:399-404.
24. Brott T, Thalinger K, Hertzberg V. Hypertension as a risk factor for spontaneous intracerebral hemorrhage. Stroke. 1986;17:1078-1083.
25. Qureshi AI, Tuhrim S, Broderick JP, Batjer HH, Hondo H, Hanley DF. Spontaneous intracerebral hemorrhage. N Engl J Med. 2001;344:1450-1460.
26. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994;120:897-902.
27. Kase CS, Robinson RK, Stein RW, et al. Anticoagulant-related intracerebral hemorrhage. Neurology. 1985;35:943-948.
28. Mattle H, Kohler S, Huber P, Rohner M, Steinsiepe KF. Anticoagulation-related intracranial extracerebral haemorrhage. J Neurol Neurosurg Psychiatry. 1989; 52:829-837.
29. Wintzen AR, de Jonge H, Loeliger EA, Bots GTA. The risk of intracerebral hemorrhage during oral anticoagulant treatment: a population study. Ann Neurol 1984; 16:553-558.
30. Dawson I, van Bockel JH, Ferrari MD, van der Meer FJ, Brand R, Terpstra JL. Ischemic and hemorrhagic stroke in patients on oral anticoagulants after reconstruction for chronic lower limb ischemia. Stroke. 1993;24:1655-1663.
31. Roos J, van Joost HE. The cause of bleeding during anticoagulant treatment. Acta Med Scand. 1965;178:129-131.
32. Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med. 1996;156:409-416.
33. Wintzen AR, Tijssen JGP. Subdural hematoma and oral anticoagulant therapy. Arch Neurol. 1982;39:69-72.
34. Jones NR, Blumberg PC, North JB. Acute subdural hematomas: aetiology, pathology and outcome. Aust N Z J Surg. 1986;56:907-913.
35. Black DW. Subdural hematoma: a retrospective study ofthe "great neurological imitator." Postgrad Med. 1985;78:107-114.
36. Christiaens JL, Combelles G, Bousquet C, et al. Hémmorragies intra-crâniennes et intra-rachidiennes chez des malades sous traitment anticoagulant: a propos de 33 cas. Lille Med. 1980;25:178-182.
37. Fihn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RH. The risk for and severity of bleeding complications in elderly patients treated with warfarin: the National Consortium of Anticoagulation Clinics. Ann Intern Med. 1996; 124;970-979.
38. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT): Italian Study on Complications of Oral Anticoagulant Therapy. Lancet. 1996;348: 423-428.
39. van der Meer FJM, Posendaal FR, Vanderbroucke JP, Briet E. Bleeding complications in oral anticoagulant therapy. Arch Intern Med. 1993;153:1557-1562.
40. Dahl T, Abildgaard U, Sandset PM. Long-term anticoagulant therapy in cerebrovascular disease: does bleeding outweigh the benefit? J Intern Med. 1995;237: 323-329.
41. Launbjerg J, Egeblad H, Heaf J, Nielsen NH, Fugleholm AM, Ladefoged K. Bleeding complications to oral anticoagulant therapy: multivariate analysis of 1010 treatment years in 551 outpatients. J Intern Med. 1991;229:351-355.
42. White RH, McKittrick T, Takakuwa J, Callahan C, McDonell M, Fihn S. Management and prognosis of life-threatening bleeding during warfarin therapy. Arch Intern Med. 1996;156:1197-1201.
43. Petty GW, Lennihan L, Mohr JP, et al. Complications of long-term anticoagulation. Ann Neurol. 1988;23:570-574.
44. Levine MN, Raskob G, Hirsh J. Hemorrhagic complications of long-term anticoagulant therapy. Chest. 1989;95(suppl):26S-36S.
45. Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol. 1997;42:857-865.
46. European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med. 1995;333:5-10.
47. European Atrial Fibrillation Trial Study Group. Secondary prevention on non-rheumatic atrial fibriliation after transient ischemic attack or minor stroke. Lancet. 1993;342:1255-1262.
48. McVay PA, Toy PTCY. Lack of increased bleeding after liver biopsy in patients with mild hemostatic abnormalities. Am J Clin Pathol. 1990;94:747-753.
49. McVay PA, Toy PTCY. Lack of increased bleeding after paracentesis and thoracentesis in patients with mild coagulation abnormalities. Transfusion. 1991;31: 164-171.
50. Rintels PB, Kenney RM, Crowley JP. Therapeutic support of patients with thrombocytopenia. Hematol Oncol Clin North Am. 1994;8:1131-1157.
51. White RH, Beyth R, Zhou H, et al. Major bleeding after hospitalization for deep venous thrombosis. Am J Med. 1999;107:414-424.
52. Brigden ML, Kay C, Le A, Graydon C, McLeod B. Audit of the frequency and clinical response to excessive oral anticoagulation in an out-patient population. Am J Hematol. 1998;59:22-27.
53. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med. 1989;87:144-152.
54. Isaacs C, Paltiel O, Blake G, Beaudet M, Conochie L, Leclerc J. Age-associated risks of prophylactic anticoagulation in the setting of hip fracture. Am J Med. 1994;96:487-491.
55. McMahan DA, Smith DM, Carey MA, Zhou XH. Risk of major hemorrhage for outpatients treated with warfarin. J Gen Intern Med. 1998;13:311-316.
56. Pettiti D, Strom B, Melmon K. Duration of warfarin anticoagulation therapy and the probabilities of recurrent thromboembolism and hemorrhage. Am J Med. 1986; 81:255-259.
57. Fihn SD, McDonnell M, Martin D, et al, for the Warfarin Optimized Outpatient Follow-up Study Group. Risk factors for complications of chronic anticoagulation: a multicenter study. Ann Intem Med. 1993;118:511-520.
58. Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest. 2001;119(suppl):108S-121S.
59. Hylek EM, Heiman H, Skates SJ, Sheehan MA, Singer DE, Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA. 1998;279:657-662.
60. Man-Son-Hing M, Laupacis A, O'Connor AM, et al. Development of a decision aid for patients with atrial fibrillation who are considering antithrombotic therapy. J Gen Intern Med. 2000;15:723-730.
61. Hull R, Hirsh J, Jay R, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med. 1982;307:1676-1681.
62. Turpie AG, Gunstensen J, Hirsh J, Nelson H, Gent M. Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet. 1988;1:1242-1245.
63. Saour JN, Sieck JO, Mamo LA, et al. Trial of two different intensities of anticoagulation in patients with prosthetic heart valves. N Engl J Med. 1990;322:428-432.
64. Hylek EM. Oral anticoagulants: pharmacologic issues for use in the elderly. Clin Geriatr Med. 2001;17:1-13.
65. Hylek E, Go A, Chang Y, et al. Increasing age is not associated with poorer anticoagulation control in outpatients with nonvalvular atrial fibrillation [abstract]. J Am Geriatr Soc. 2000;48:S58.
66. Petitti DB, Strom BL, Melmon KL. Prothrombin time ratio and other factors associated with bleeding in patients treated with warfarin. J Clin Epidemiol. 1989; 42:759-764.
67. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II study. Lancet. 1994;343:687-691.
68. Beyth RJ, Landefeld CS. Are older patients at increased risk for major bleeding during anticoagulant therapy [abstract]? Clin Res. 1992;40:552A.
69. Gurwitz JH, Goldberg RJ, Holden A, Knapic N, Ansell J. Age-related risks of long-term oral anticoagulant therapy. Arch Intern Med. 1988;148:1733-1736.
70. Stroke Prevention in Atrial Fibrillation Investigators. Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation. J Stroke Cerebrovasc Dis. 1995;5:147-157.
71. Canadian Task Force on Preventive Health Care. History and Methods. Ottawa, Ontario: Health Canada. Available at: http://www.ctfphc.org. Accessed October 29, 2001.
72. Man-Son-Hing M, Laupacis A, O'Connor AM, et al. Warfarin for atrial fibrillation: the patient's perspective. Arch Intern Med. 1996;156:1841-1848.
73. Gage BF, Cardinalli AB, Owens DK. Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation. Stroke. 1998; 29:1083-1091.
74. Thomson RG, Parkin D, Eccles M, Sudlow M, Robinson A. Decision analysis and guidelines for anticoagulant therapy to prevent stroke in patients with atrial fibrillation. Lancet. 2000;355:956-962.
75. Hart RG. Anticoagulation therapy for patients with atrial fibrillation [letter]. CMAJ. 2000;163:956-957.
76. Stafford RS, Singer DE. National patterns of warfarin use in atrial fibrillation. Arch Intern Med. 1996;156:2537-2541.
77. Antani MR, Beyth RJ, Covinsky KE, et al. Failure to prescribe warfarin to patients with nonrheumatic atrial fibrillation. J Gen Intern Med. 1996;11:713-720.
78. Lawson F, McAlister F, Ackman M, Ikuta R, Montague T. The utilization of antithrombotic prophylaxis for atrial fibrillation in a geriatric rehabilitation hospital. J Am Geriatr Soc. 1996;44:708-711.
79. Albers GW, Yim JM, Belew KM, et al. Status of antithrombotic therapy for patients with atrial fibrillation in university hospitals. Arch Intern Med. 1996;156: 2311-2316.
80. Sudlow M, Thomson R, Rodgers H, Livingstone S, Kenny RA. The effect of age and quality of life in doctors' decisions to anticoagulate patients with atrial fibrillation. Age Ageing. 1998;27:285-289.
81. Matchar DB, Samsa GP, Cohen SJ. Should we just let the anti-coagulation service do it? the conundrum of anticoagulation for atrial fibrillation. J Gen Intern Med. 1996; 11: 768-770.
82. Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med. 1998;158:1641-1647.
83. Tversky A, Kahneman D. Judgement under uncertainty: heuristics and biases. Science. 1974;185:1124-1131.
84. Eraker SA, Polister P. How decisions are reached: physician and patient. Ann Intern Med. 1982;97:262-268.
85. Asch DA, Baron J, Hershey JC, et al. Omission bias and pertussis vaccination. Med Decis Making. 1994;14:118-123.
86. Feinstein AR. The "chagrin factor" and qualitative decision analysis. Arch Intern Med. 1985;145:1257-1259.